Publications by authors named "Dominic Labriola"
Article Synopsis
- Resmetirom, a thyroid-hormone receptor-β agonist, has been approved for treating metabolic dysfunction-associated steatohepatitis (MASH), and its impact on health-related quality of life (HRQL) was studied in this clinical trial.
- In a 54-month double-blind trial with nearly 1,000 patients, those receiving resmetirom (80 mg or 100 mg) showed significant improvements in various HRQL measures compared to a placebo group, particularly in the Worry domain of the Chronic Liver Disease Questionnaire (CLDQ-NAFLD).
- The study concluded that patients with MASH/NASH who improved their fibrosis or resolved MASH experienced notable HRQL enhancements, indicating that resmeti
Article Synopsis
- * A phase 3 trial is underway, where adult participants with confirmed NASH are randomly assigned to receive either resmetirom (80 mg or 100 mg) or a placebo, with primary goals of NASH resolution and improvement in fibrosis after 52 weeks.
- * In the trial's results, a significantly higher percentage of patients taking resmetirom experienced NASH resolution and fibrosis improvement compared to those on placebo, along with notable reductions in cholesterol levels, although some participants did report diarrhea.
Article Synopsis
- Nonalcoholic steatohepatitis (NASH) is a serious liver disease that currently has no approved treatments; a recent trial called MAESTRO-NAFLD-1 tested a drug called resmetirom for safety and efficacy in adults with this condition.
- In the 52-week trial involving over 1,000 participants, patients were given different doses of resmetirom or a placebo, and researchers focused on side effects and various health markers like liver fat and cholesterol levels.
- The results showed that resmetirom was generally safe and well tolerated, with reported side effects like diarrhea and nausea, while also leading to significant reductions in liver fat and cholesterol levels compared to placebo, suggesting its potential for further development
Background: We explored whether the effectiveness of immune checkpoint inhibitors (ICIs) can be characterized by incorporating a composite of duration of response (DOR) to complement traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria for objective response rate (ORR) in an intent-to-treat (ITT) population. Furthermore, the correlation of this novel endpoint, characterized by the restricted mean time in response (RMTR), with overall survival (OS) will be examined.
Methods: We analyzed ORR alone or in combination with DOR (RMTR) in available phase I, II, and III trials evaluating nivolumab monotherapy or in combination with ipilimumab across solid tumor types.
In a placebo-controlled, double-blind German multicenter study (seven sites) the efficacy of naltrexone as an adjunctive treatment in alcoholism to maintain abstinence was assessed for 12 weeks. A total of 171 detoxified patients (97.7% met the DSM-III-R criteria for alcohol dependence) were included.
View Article and Find Full Text PDF